Document:

THIS  WARRANT  AND THE SHARES OF COMMON  STOCK  ISSUABLE  UPON  EXERCISE OF THIS
WARRANT HAVE NOT BEEN  REGISTERED  UNDER THE  SECURITIES ACT OF 1933, AS AMENDED
(THE "ACT") OR ANY STATE  SECURITIES  LAWS, AND ARE  "RESTRICTED  SECURITIES" AS
THAT TERM IS DEFINED IN RULE 144 UNDER THE ACT. THE  SECURITIES MAY NOT BE SOLD,
OFFERED FOR SALE, OR OTHERWISE  TRANSFERRED  UNLESS AND UNTIL  REGISTERED  UNDER
SAID ACT AND ANY  APPLICABLE  STATE  SECURITIES  LAWS,  OR UPON  RECEIPT  BY THE
COMPANY  OF AN  OPINION  OF  COUNSEL  SATISFACTORY  TO  THE  COMPANY  THAT  SUCH
REGISTRATION IS NOT REQUIRED.

                                                                 Warrant No. EG1

                  WARRANT TO PURCHASE SHARES OF COMMON STOCK

                            ISSUE DATE: MARCH 1, 2006

      This  certifies  that Eric  Gombrich,  an individual  resident of Alberta,
Canada (or any valid transferee thereof, the "Holder"),  for value received,  is
entitled to purchase  from  Molecular  Diagnostics,  Inc.  (d/b/a  Cytocore),  a
Delaware  corporation  with its principal  business  office located at 414 North
Orleans Street, Suite 502, Chicago, Illinois 60610 (together with its successors
and  assigns,  the  "Company"),  subject to the terms and  conditions  set forth
below, at any time or from time to time on and after the Issue Date as set forth
above  and  before  3:00  p.m.  (Eastern  Daylight  Time) on July 31,  2009 (the
"Expiration  Date"),  300,000 shares of common stock, $.001 par value per share,
of the  Company  ("Common  Stock"),  at a price of $0.10 per  share.  The shares
purchasable  upon  exercise of this Warrant,  and the purchase  price per share,
each as adjusted from time to time  pursuant to the  provisions of this Warrant,
are hereinafter  referred to as the "Warrant  Shares" and the "Purchase  Price,"
respectively.

      1. EXERCISE OF THE WARRANT.

            (a)  EXERCISE.  The Holder may,  at the  Holder's  option,  elect to
exercise this Warrant,  in whole or in part, at any time or from time to time on
or after the Issue Date but prior to 3:00 p.m.  (Eastern  Daylight  Time) on the
Expiration Date, by surrendering  this Warrant,  with the purchase form appended
hereto  as  EXHIBIT  I duly  executed  by or on  behalf  of the  Holder,  at the
principal  office  of the  Company,  or at such  other  office  or agency as the
Company may  designate,  accompanied  by payment in full, in lawful money of the
United States, of the Purchase Price payable in respect of the number of Warrant
Shares purchased upon such exercise.  In no event shall any such exercise be for
fewer than  10,000  Warrant  Shares  unless  fewer than an  aggregate  of 10,000
Warrant Shares are then purchasable  under all outstanding  Warrants held by the
Holder.  Payment of the aggregate Purchase Price may be made in cash,  certified
or bank check, or wire transfer of immediately available funds.

            (b) EXERCISE  DATE AND STATUS AS HOLDER OF SHARES.  Each exercise of
this  Warrant  shall be deemed to have been  effected  immediately  prior to the
close of business on the day on which this Warrant  shall have been  surrendered
to the Company as provided in Subsection  1(a) above (the "Exercise  Date").  At
such time,  the person or  persons in whose name or names any  certificates  for
Warrant  Shares shall be issuable  upon such  exercise as provided in Subsection
1(c) below shall be deemed to have become the holder or holders of record of the
Warrant Shares represented by such certificates.

<PAGE>

            (c)  ISSUANCE  OF  CERTIFICATES.  As soon as  practicable  after the
exercise  of this  Warrant  in whole  or in part,  and in any  event  within  10
business days thereafter,  the Company, at its expense,  will cause to be issued
in the name of, and delivered to, the Holder,  or as the Holder (upon payment by
the Holder of any applicable transfer taxes) may direct:

                  (i) a  certificate  or  certificates  for the  number  of full
Warrant Shares to which the Holder shall be entitled upon such exercise plus, in
lieu of any  fractional  share to which the Holder would  otherwise be entitled,
cash in an amount determined pursuant to Section 3 hereof; and

                  (ii) in case such  exercise is in part only,  a new warrant or
warrants (dated the date hereof) of like tenor,  calling in the aggregate on the
face or faces  thereof for the number of Warrant  Shares equal  (without  giving
effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant  minus the number of Warrant  Shares for which this Warrant
was so exercised.

            (d) WARRANT SHARES. The Warrant Shares issued upon any such exercise
of this Warrant shall be validly issued, fully paid and non-assessable.

      2. ADJUSTMENTS.

            (a)  ADJUSTMENT  FOR STOCK SPLITS AND  COMBINATIONS.  If the Company
shall at any time or from time to time after the Issue Date (or, if this Warrant
was issued upon partial  exercise of, or in replacement  of, another  warrant of
like  tenor,  then the date on which such  original  warrant  was first  issued)
(either  such date being  referred to as the  "Original  Issue  Date")  effect a
subdivision of the outstanding  Common Stock,  the Purchase Price then in effect
immediately before that subdivision shall be proportionately  decreased.  If the
Company  shall at any time or from time to time  after the  Original  Issue Date
combine the  outstanding  shares of Common  Stock,  the  Purchase  Price then in
effect immediately  before the combination shall be  proportionately  increased.
Any adjustment under this Subsection 2(a) shall become effective at the close of
business on the date the subdivision or combination becomes effective.

            (b) ADJUSTMENT FOR CERTAIN DIVIDENDS AND DISTRIBUTIONS. In the event
the Company at any time or from time to time after the Original Issue Date shall
make or issue, or fix a record date for the  determination  of holders of Common
Stock entitled to receive, a dividend or other distribution payable in shares of
Common  Stock,  then and in each such  event the  Purchase  Price then in effect
immediately before such event shall be decreased as of the time of such issuance
or, in the event such a record  date shall have been  fixed,  as of the close of
business on such record date, by  multiplying  the Purchase Price then in effect
by a fraction:

                        (1) the numerator of which shall be the total
number of shares of Common Stock issued and outstanding immediately prior to the
time of such issuance or the close of business on such record date, and

                                      - 2 -
<PAGE>

                        (2) the denominator of which shall be the total
number of shares of Common Stock issued and outstanding immediately prior to the
time of such  issuance  or the close of  business  on such  record date plus the
number of shares of  Common  Stock  issuable  in  payment  of such  dividend  or
distribution;

PROVIDED,  HOWEVER,  that if such  record  date  shall  have been fixed and such
dividend is not fully paid or if such distribution is not fully made on the date
fixed  therefor,  the Purchase  Price shall be recomputed  accordingly as of the
close of business on such record date and thereafter the Purchase Price shall be
adjusted  pursuant to this  Subsection  2(b) as of the time of actual payment of
such dividends or distributions.

            (c) ADJUSTMENT IN NUMBER OF WARRANT  SHARES.  When any adjustment is
required to be made to the Purchase Price pursuant to Subsections  2(a) or 2(b),
the number of Warrant Shares purchasable upon the exercise of this Warrant shall
be changed to the  number  determined  by  dividing  (i) an amount  equal to the
number of shares issuable upon the exercise of this Warrant immediately prior to
such adjustment, multiplied by the Purchase Price in effect immediately prior to
such  adjustment,  by (ii) the Purchase Price in effect  immediately  after such
adjustment.

            (d)  ADJUSTMENT  FOR  REORGANIZATION.   If  there  shall  occur  any
reorganization,  recapitalization,  reclassification,  consolidation  or  merger
involving  the Company in which the Common Stock is converted  into or exchanged
for  securities,  cash or other  property  (other than a transaction  covered by
Subsections 2(a) or 2(b)) (collectively,  a  "Reorganization"),  then, following
such Reorganization,  the Holder shall receive upon exercise hereof the kind and
amount of  securities,  cash or other  property which the Holder would have been
entitled to receive pursuant to such  Reorganization  if such exercise had taken
place immediately prior to such  Reorganization.  In any such case,  appropriate
adjustment  (as  determined  in good  faith by the  Board)  shall be made in the
application  of the  provisions  set forth herein with respect to the rights and
interests  thereafter of the Holder, to the end that the provisions set forth in
this  Section 2  (including  provisions  with  respect  to  changes in and other
adjustments of the Purchase Price) shall thereafter be applicable,  as nearly as
reasonably  may be,  in  relation  to any  securities,  cash or  other  property
thereafter deliverable upon the exercise of this Warrant.

            (e) NO ADJUSTMENTS IN CERTAIN CASES.  No adjustment in the number of
Warrant Shares purchasable pursuant to this Warrant shall be required unless the
adjustment  would require an increase or decrease of at least one percent (1.0%)
in the number of Warrant  Shares  then  purchasable  upon the  exercise  of this
Warrant.  Except as  provided  in this  Section 2, no other  adjustments  in the
number, kind or price of shares constituting Warrant Shares shall be made during
the term, or upon the exercise,  of this Warrant.  Further, no adjustments shall
be made  pursuant  to this  Section  2 hereof  in  connection  with the grant or
exercise of presently  authorized  or  outstanding  options to purchase,  or the
issuance of shares of Common Stock  under,  the  Company's  director or employee
benefit, option and incentive plans.

            (f) TREASURY STOCK. For purposes of this Section 2, shares of Common
Stock owned or held at any relevant time by, or for the account of, the Company,
in its treasury or otherwise, shall not be deemed to be outstanding for purposes
of the calculations and adjustments herein described.

                                      - 3 -
<PAGE>

      3. FRACTIONAL  SHARES. The Company shall not be required upon the exercise
of this  Warrant to issue any  fractional  shares,  but shall pay in cash to the
Holder an amount equal to such fraction  multiplied by the fair market value per
share of Common Stock, as determined by the Board of Directors in good faith.

      4. INVESTMENT REPRESENTATIONS.  The initial Holder represents and warrants
to the Company as follows:

            (a)  INVESTMENT.  The Holder is acquiring this Warrant,  and (if and
when such Holder  exercises this Warrant) will acquire the Warrant  Shares,  for
such Holder's own account for  investment and not with a view to, or for sale in
connection with, any  distribution  thereof,  nor with any present  intention of
distributing  or selling the same; and the Holder has no present or contemplated
agreement,  undertaking,  arrangement,  obligation,  indebtedness  or commitment
providing for the disposition thereof.

            (b) ACCREDITED INVESTOR.  The Holder is an "accredited  investor" as
defined in Rule 501(a) under the Act.

            (c)  EXPERIENCE.  The Holder has made such  inquiry  concerning  the
Company and its business and personnel as the Holder has deemed appropriate; and
the Holder has sufficient  knowledge and experience in finance and business that
the Holder is capable of evaluating the risks and merits of an investment in the
Company.

      5. TRANSFERS, ETC.

            (a) This Warrant and the Warrant  Shares shall not be offered,  sold
or transferred unless either (i) they first shall have been registered under the
Act and any applicable  state  securities  laws, or (ii) the Company first shall
have been  furnished  with an  opinion  of legal  counsel,  satisfactory  to the
Company,  to the effect  that such  offer,  sale or  transfer is exempt from the
registration requirements of the Act and any applicable state securities laws.

            (b) Each Warrant and certificate  representing  Warrant Shares shall
bear a legend substantially in the following form:

                  "The securities  represented by this certificate have not been
                  registered  under the Securities  Act of 1933, as amended,  or
                  any state  securities  laws,  and may not be offered,  sold or
                  otherwise  transferred,  pledged  or  hypothecated  unless and
                  until  such  securities  are  registered  under  such  act and
                  applicable  state  securities  laws or an  opinion  of counsel
                  reasonably  satisfactory  to the  Company is  obtained  to the
                  effect that such registration is not required."

      The foregoing legend shall be removed from the  certificates  representing
any Warrant Shares,  at the request of the holder thereof,  at such time as they
become eligible for resale pursuant to Rule 144 under the Act.

                                      - 4 -
<PAGE>

            (c) The Company  will  maintain a register  containing  the name and
address of the  Holder of this  Warrant.  The  Holder  may  change the  Holder's
address  as shown on the  warrant  register  by  written  notice to the  Company
requesting such change.

            (d) Subject to the provisions of clauses (a) and (b) of this Section
5, this Warrant and all rights hereunder are transferable,  in whole or in part,
upon surrender of this Warrant with a properly executed  assignment (in the form
of EXHIBIT II hereto) at the  principal  office of the  Company  (or, if another
office or agency has been  designated by the Company for such  purpose,  then at
such other office or agency).  Upon the presentation and surrender of such items
to the  Company,  the Company  shall  execute and deliver to the  transferee  or
transferees  of this  Warrant  a new  Warrant  or  Warrants,  in the name of the
transferee or  transferees  named in the  assignment,  and this Warrant shall at
that time be canceled to the extent transferred.

      6. NO IMPAIRMENT; ADJUSTMENT OF PAR VALUE.

            (a) The Company will not, by amendment of its charter or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities  or any other  voluntary  action,  avoid or seek to avoid the
observance or performance  of any of the terms of this Warrant,  but will at all
times in good  faith  assist in the  carrying  out of all such  terms and in the
taking of all such action as may be necessary or appropriate in order to protect
the rights of the Holder against impairment.

            (b) Before taking any action that would cause an adjustment reducing
the  Purchase  Price per share below the then par value of the shares of Warrant
Shares  issuable  upon  exercise  of the  Warrant,  the  Company  will  take any
corporate action that may be necessary in order that the Company may validly and
legally  issue fully paid and  non-assessable  shares of such Warrant  Shares at
such adjusted price.

      7. RECORD DATE, ETC. In the event:

            (a) the  Company  shall  take a record of the  holders of its Common
Stock (or other stock or securities at the time deliverable upon the exercise of
this  Warrant)  for the purpose of  entitling  or  enabling  them to receive any
dividend  or other  distribution,  or to receive any right to  subscribe  for or
purchase any shares of stock of any class or any other securities, or to receive
any other right; or

            (b)  of   any   capital   reorganization   of   the   Company,   any
reclassification of the Common Stock of the Company, any consolidation or merger
of the Company with or into another  corporation  (other than a consolidation or
merger in which the Company is the surviving  entity and its Common Stock is not
converted  into or  exchanged  for any other  securities  or  property),  or any
transfer of all or substantially all of the assets of the Company; or

            (c) of the  voluntary or  involuntary  dissolution,  liquidation  or
winding-up of the Company,

then,  and in each such case,  the Company  will send or cause to be sent to the
Holder a notice  specifying,  as the case may be, (i) the  record  date for such
dividend,  distribution or right, and the amount and character of such dividend,
distribution or right, or (ii) the effective date on which such  reorganization,
reclassification,  consolidation,  merger, transfer, dissolution, liquidation or
winding-up is to take place,  and the time,  if any is to be fixed,  as of which
the holders of record of Common Stock (or such other stock or  securities at the
time  deliverable  upon the  exercise  of this  Warrant)  shall be  entitled  to
exchange  their shares of Common Stock (or such other stock or  securities)  for
securities   or   other   property   deliverable   upon   such   reorganization,
reclassification,  consolidation,  merger, transfer, dissolution, liquidation or
winding-up.  Such notice shall be sent at least 10 days prior to the record date
or effective date for the event specified in such notice.

                                      - 5 -
<PAGE>

      8.  RESERVATION  OF STOCK.  The Company will at all times reserve and keep
available,  solely for issuance and delivery  upon the exercise of this Warrant,
such number of Warrant Shares and other securities, cash and/or property as from
time to time shall be issuable upon the exercise of this Warrant.

      9. EXCHANGE OR REPLACEMENT OF WARRANTS.

            (a) Upon the  surrender  by the  Holder  of this  Warrant,  properly
endorsed,  to the Company at the  principal  office of the Company,  the Company
will,  subject to the  provisions  of Section 5 hereof,  issue and deliver to or
upon the  order of the  Holder,  at the  Company's  expense,  a new  Warrant  or
Warrants of like tenor, in the name of the Holder or as the Holder (upon payment
by the  Holder of any  applicable  transfer  taxes) may  direct,  calling in the
aggregate on the face or faces  thereof for the number of shares of Common Stock
(or other securities,  cash and/or property) then issuable upon exercise of this
Warrant.

            (b) Upon receipt of evidence reasonably  satisfactory to the Company
of the loss,  theft,  destruction or mutilation of this Warrant and (in the case
of loss,  theft or  destruction)  upon delivery of an indemnity  agreement (with
surety if  reasonably  required)  in an amount  reasonably  satisfactory  to the
Company,  or (in the case of mutilation) upon surrender and cancellation of this
Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor.

      10. NOTICES.  All notices and other communications from the Company to the
Holder in connection  herewith shall be mailed by certified or registered  mail,
postage prepaid,  or sent via a reputable  nationwide  overnight courier service
guaranteeing  next business day delivery,  to the address last  furnished to the
Company in writing by the Holder. All notices and other  communications from the
Holder to the Company in  connection  herewith  shall be mailed by  certified or
registered mail, postage prepaid, or sent via a reputable  nationwide  overnight
courier service  guaranteeing next business day delivery,  to the Company at its
principal  office set forth above.  If the Company should at any time change the
location of its  principal  office to a place other than as set forth above,  it
shall give prompt  written notice to the Holder and thereafter all references in
this  Warrant to the location of its  principal  office at the  particular  time
shall be as so  specified in such  notice.  All such notices and  communications
shall be deemed  delivered (a) three business days after being sent by certified
or registered  mail,  return  receipt  requested,  postage  prepaid,  or (b) one
business  day after  being sent via a  reputable  nationwide  overnight  courier
service guaranteeing next business day delivery.

      11. NO RIGHTS AS STOCKHOLDER;  NO LIABILITY.  No provision of this Warrant
shall be  construed  as  conferring  upon the  Holder  hereof the right to vote,
consent,  receive  dividends or receive  notice as a  stockholder  in respect of
meetings of  stockholders  for the  election of  directors of the Company or any
other matter  whatsoever  as a  stockholder  of the  Company.  In the absence of
affirmative  action by the Holder hereof to purchase  shares of Common Stock, no
provision  hereof  shall  give  rise to any  liability  of such  Holder  for the
purchase  price or as a stockholder  of the Company,  whether such  liability is
asserted by the Company or by creditors of the Company.

                                      - 6 -
<PAGE>

      12. PAYMENT OF TAXES. The Company will pay all documentary stamp taxes, if
any,  attributable  to the  initial  issuance  of this  Warrant or the shares of
Common Stock comprising the Warrant Shares; PROVIDED, HOWEVER, the Company shall
not be required to pay any tax that may be payable in respect of any transfer of
this Warrant or Warrant Shares.

      13. AMENDMENT OR WAIVER. Any term of this Warrant may be amended or waived
only by an instrument in writing  signed by the party against which  enforcement
of the  change  or waiver is  sought.  No  waivers  of any  term,  condition  or
provision of this Warrant, in any one or more instances,  shall be deemed to be,
or construed as, a further or continuing  waiver of any such term,  condition or
provision or any other term, condition or provision hereof.

      14.  SECTION  HEADINGS.  The section  headings in this Warrant are for the
convenience  of the parties only and in no way alter,  modify,  amend,  limit or
restrict the contractual obligations of the parties.

      15. SEVERABILITY.  If any provision of this Warrant shall be held invalid,
illegal or unenforceable,  such invalidity, illegality or unenforceability shall
not affect any other  provision of this Warrant and, to this end, the provisions
hereof are severable.

      16.  ASSIGNMENT.  This  Warrant  shall be  binding  upon and  inure to the
benefit  of  the   parties   hereto  and  their   respective   heirs,   personal
representatives, successors and permitted assigns.

      17.  GOVERNING  LAW.  This  Warrant  will be governed by and  construed in
accordance with the internal laws of the State of Delaware (without reference to
the conflicts of law provisions thereof).

      18.  SIGNATURES.  This Warrant may be executed in one or more counterparts
by facsimile signature.

                        (Signature appears on next page).

                                      - 7 -
<PAGE>

      EFFECTIVE as of the Issue Date indicated above.

                                    MOLECULAR DIAGNOSTICS, INC.

                                    By:
                                       -------------------------------------
                                    Title:
                                          ----------------------------------

                                      - 8 -
<PAGE>

                                                                       EXHIBIT I

                                  PURCHASE FORM

To:                                                      Dated:
   -----------------------                                     ----------------

      The  undersigned,  pursuant to the  provisions  set forth in the  attached
Warrant (No.  EG1),  hereby  elects to purchase  ________________  shares of the
Common Stock of Molecular Diagnostics, Inc. (d/b/a Cytocore) by such Warrant.

      The undersigned herewith makes payment of the full Purchase Price for such
shares at the price per share  provided for in such Warrant.  Such payment shall
be in the  aggregate  amount of $  ________________  in cash,  certified or bank
check, or wire transfer of immediately available funds.

                                    Signature:
                                              --------------------------------

                                    Address:
                                             ---------------------------------

                                             ---------------------------------

                                      - 9 -
<PAGE>

                                                                    EXHIBIT II

                                 ASSIGNMENT FORM

      FOR VALUE RECEIVED, ________________________________________ hereby sells,
assigns and  transfers all of the rights of the  undersigned  under the attached
Warrant  (No. EG1) with  respect  to the  number  of shares of Common  Stock of
Molecular  Diagnostics,  Inc. (d/b/a Cytocore)  covered thereby set forth below,
unto:

NAME OF ASSIGNEE              ADDRESS                    NO. OF SHARES
----------------              -------                    -------------

Dated:                              Signature:
      ------------------------                --------------------------------

Signature Guaranteed:

By:
   ---------------------------

The signature should be guaranteed by an eligible guarantor  institution (banks,
stockbrokers, savings and loan associations and credit unions with membership in
an approved  signature  guarantee  medallion program) pursuant to Rule 17A under
the Securities Exchange Act of 1934, as amended.

                                     - 10 -COLUMBIA

                LABORATORIES,
                  INC.

              

            	 	354
              Eisenhower Parkway
              Second
                Floor –
                Plaza I

              Livingston,
                NJ

              

              TEL:
                (973) 994-3999

              FAX:
                (973) 994-3001

            

    

    
 

    Exhibit
      10.62

    

    April
      14,
      2006

    

    VIA
      FACSIMILE (919) 998-2090

    PharmaBio
      Development Inc.

    Attention:
      Ronald J. Wooten, President

    4709
      Creekstone Drive

    Suite
      200, Riverbirch Building

    Durham,
      North Carolina 27703

    

    Re:
      Letter Agreement Supplement to Striant® Investment and Royalty
      Agreement

    

    Dear
      Ron:

     

    We
      refer
      to the Investment and Royalty Agreement between Columbia Laboratories, Inc.
      (“Columbia”) and PharmaBio Development Inc. (“PharmaBio”), dated March 5, 2003
      (the “Agreement”). The purpose of this letter agreement is to supplement the
      Agreement by setting forth the terms and conditions under which Columbia will
      pay certain royalties under Section 2.3 of the Agreement on a date earlier
      than
      otherwise required under such section. Capitalized terms that are not defined
      in
      this letter agreement have the same meaning as set forth in the
      Agreement.

     

    Pursuant
      to Section 2.3 of the Agreement, if by the end of the third Annual Period (i.e.
      September 30, 2006), PharmaBio has not received at least $13 million in
      aggregate royalties under Section 2.3 (with respect to Net Sales for the first
      three Annual Periods), then Columbia is required to pay PharmaBio not later
      than
      45 days following the end of the calendar quarter (i.e. November 14, 2006)
      the
      difference between the amount of royalties actually received and $13 million
      (the “True Up Payment”). Columbia now expects the amount of the True Up Payment
      to be approximately $12 million. 

     

    Columbia
      proposes to pay $12 million of the True Up Payment on an accelerated basis
      via
      wire transfer in immediately available funds to an account designated by
      PharmaBio. Specifically, Columbia agrees to pay PharmaBio on April 14, 2006,
      Eleven Million Five Hundred Eighty-Five Thousand Two Hundred Thirty-Five Dollars
      ($11,585,235) (the “Early Payment”), which is the present value of a $12 million
      True Up Payment using a six percent (6%) annual discount factor. In
      consideration of such payment, PharmaBio agrees that PharmaBio will be deemed,
      solely for purposes of the Agreement, to have received royalties by the end
      of
      the third Annual Period of $12 million plus royalties actually received by
      PharmaBio with respect to Net Sales through September 30, 2006, subject to
      the
      last sentence of the next paragraph. 

     

    Following
      the end of the third Annual Period, Columbia will determine the amount of the
      actual True Up Payment that is due and payable as required by Section 2.3.
      For
      clarity, the amount of the True Up Payment will equal the excess, if any, of
      $13
      million over the sum of (i) the royalties actually received by PharmaBio (other
      than
      royalties deemed paid on account of the Early Payment) and (ii) $12 million
      (royalties deemed paid on account of the Early Payment) (the sum of (i) and
      (ii), the “Aggregate Royalties”). However, if the Aggregate Royalties exceed $13
      million, then PharmaBio shall pay to Columbia the excess of the Aggregate
      Royalties over $13 million (such amount, the “Excess Royalties Amount”) within
      fifteen (15) days after PharmaBio receives Columbia’s written calculation of the
      Excess Royalties Amount, and, solely for purposes of the Agreement, the amount
      of royalties deemed received by PharmaBio through the end of the third Annual
      Period shall be $13 million.

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

     

    For
      the
      avoidance of doubt, this letter agreement supplements and does not amend the
      Agreement, which remains in full force and effect. Without limiting the
      foregoing, Columbia’s payment of the Early Payment does not affect Columbia’s
      obligation to pay royalties with respect to Striant® Net Sales during the
      quarter ended June 30, 2006.

     

    This
      letter agreement and any amendment hereto may be executed in counterparts,
      each
      of which when executed and delivered shall be deemed to be an original and
      all
      of which counterparts taken together shall constitute but one and the same
      instrument. The execution of this letter agreement and any such amendment by
      either party will not become effective until counterparts hereof have been
      executed and delivered by both parties hereto. This letter agreement may be
      executed by either party by delivery of such party’s signature thereon by
      facsimile or by email transmission in portable digital format, or similar
      format. 

     

    This
      letter agreement shall be governed by and construed in accordance with the
      Laws
      of the State of Delaware, as applied to agreements executed and performed
      entirely in the State of Delaware, without regard to conflicts of law
      rules.

     

    Please
      acknowledge your agreement to the foregoing by countersigning this letter
      agreement on the following page.

    
      	 	 	 
	 	
              Sincerely,

               

              COLUMBIA
                LABORATORIES, INC.

            
	 
 	 
 	 
 
	 	 	
              By:      
                /s/ David L. Weinberg

            
	 	
              
                

              

            
	 	
              Name:
                 David
                L. Weinberg

              Title:  
                 Vice
                President, Finance, and

               
                Chief Financial Officer

            

    

    
    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
 

    
      PharmaBio
        Development Inc.

      April
        14,
        2006

      Page
        3
of
        3

    

     

     

    ACKNOWLEDGED
      AND ACCEPTED:

     

    PHARMABIO
      DEVELOPMENT INC.

    

    

    
      	 	 	 	 
	By:      
              /s/ Ronald John Wooten 	 	 	 
	
              
                

              

            	 	 	
            
	
              Name:  Ronald
                John Wooten 

              Title:   
                President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]